Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Carcinoma, Renal Cell × Interferon-alpha × Clear all

Phase

Phase 2 15 Phase 3 9 Phase 1/2 4 Phase 1 3 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

peginterferon alfa-2a 1 naptumomab estafenatox 1 Interferon-alpha 1 Interferon alpha-2 1 G250 monoclonal antibody 1 Anesthesia, Epidural 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00420888 2015-07-22

ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

Active Biotech AB

Phase 2/3 Completed

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡